AR014974A1 - COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINE - Google Patents
COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINEInfo
- Publication number
- AR014974A1 AR014974A1 ARP990101516A ARP990101516A AR014974A1 AR 014974 A1 AR014974 A1 AR 014974A1 AR P990101516 A ARP990101516 A AR P990101516A AR P990101516 A ARP990101516 A AR P990101516A AR 014974 A1 AR014974 A1 AR 014974A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- nr3r4
- aryl
- halo
- branched
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto con actividad sobre receptores muscarínicos, que comprenden la formula (I) en donde: X1, X2, X3, X4 y X5 se seleccionan entre C, N y O; k es 0o 1; t es 0, 1 o 2; R1 es alquilo C1-8 de cadena ramificada o recta, alquenilo C2-8, alquiniloC1-8, alquilideno C1-8, alcoxi C1-8, heteroalquilo C1-8,aminoalquilo C1-8, haloalquilo C1-8, alcoxicarbonilo C1-8, hidroxialcoxi C1-8, hidroxialquilo C1-8, -SH, alquiltio C1-8, -O-CH2-C5-6 arilo, -C(O)-C5-6 arilosustituido con alquilo C1-3 o halo; arilo C5-6 o cicloalquilo C5-6 que opcionalmente comprende 1 o más heteroátomos seleccionados entre N, S y O; -C(O)NR3R4,-NR3R4, -NR3C(O)NR4R5, -CNR3R4, -OC(O)R3, -(O)(CH2)sNR3R4 o -(CH2)sNR3R4; donde R3, R4 y R5 son iguales o diferentes; cada uno es independientementeseleccionado entre H, alquilo C1-6; arilo C5-6 que opcionalmente comprende 1 o más heteroátomos seleccionados entre N, O y S, y opcionalmente sustituido conhalo o alquilo C1-6; cicloalquilo C3-6; o R3 y R4 junto con el átomo N, cuando está presente, forman una estructura de anillo cíclico que comprende 5-6 átomosseleccionados entre C, N, S y O; y s es un entero de 0 a 8; A es arilo C5-12 o cicloalquilo C5-7; cada uno comprende opcionalmente 1 o más heteroátomosseleccionados entre N, S y O; R2 es H, amino, hidroxilo, halo, o alquilo C1-6 de cadena ramificada o recta, alquenilo C2-6, alquinilo C2-6, alcoxi C1-6,heteroalquilo C1-6, aminoalquilo C1-6, haloalquilo C1-6, alquiltio C1-6, alcoxicarbonilo C1-6, -CN, -CF3, -OR3, -COR3, NO2, -NHR3, -NHC(O)R3, -C(O)NR3R4,-NR3R4, -NR3C(O)NR4R5, -OC(O)R3, -C(O)R3R4, -O(CH2)qNR3, -CNR3R4 o -(CH2)qNR3R4; donde q es un entero desde 1 a 6; n es 0, 1, 2, 3, o 4, los grupos R2, cuandon > 1, son iguales o diferentes; p es 0 o un entero de1 a 5; Y es O, S, CHOH, -NHC(O)-, -C(O)NH-, -C(O)-, -OC(O)-, NR7 o -CH=N-, y R7 es H o alquilo C1-4; oausente; Z es CR8R9 en donde R8 y R9 se seleccionan independientemente entre H y alquilo C1-8 recto o de cadena ramificada; siempre que cuando -(CH2)p-Y- es-(CH2)3-C(O)- o -(CH2)3-S-, y X1 a X5 son C; que -A-(R2)n y R1 no están juntos: o-metil-fenilo y n-butilo, respectivamente; fenilo y n-butilo, respectivamente;A compound with activity on muscarinic receptors, comprising formula (I) wherein: X1, X2, X3, X4 and X5 are selected from C, N and O; k is 0o 1; t is 0, 1 or 2; R1 is branched or straight chain C1-8 alkyl, C2-8 alkenyl, C1-8 alkynyl, C1-8 alkylidene, C1-8 alkoxy, C1-8 heteroalkyl, C1-8 aminoalkyl, C1-8 haloalkyl, C1-8 alkoxycarbonyl , C1-8 hydroxyalkoxy, C1-8 hydroxyalkyl, -SH, C1-8 alkylthio, -O-CH2-C5-6 aryl, -C (O) -C5-6 arylsubstituted with C1-3 alkyl or halo; C5-6 aryl or C5-6 cycloalkyl optionally comprising 1 or more heteroatoms selected from N, S and O; -C (O) NR3R4, -NR3R4, -NR3C (O) NR4R5, -CNR3R4, -OC (O) R3, - (O) (CH2) sNR3R4 or - (CH2) sNR3R4; where R3, R4 and R5 are the same or different; each is independently selected from H, C1-6 alkyl; C5-6 aryl which optionally comprises 1 or more heteroatoms selected from N, O and S, and optionally substituted with halo or C1-6 alkyl; C3-6 cycloalkyl; or R3 and R4 together with the N atom, when present, form a cyclic ring structure comprising 5-6 atoms selected from C, N, S and O; and s is an integer from 0 to 8; A is C5-12 aryl or C5-7 cycloalkyl; each optionally comprises 1 or more heteroatoms selected from N, S and O; R 2 is H, amino, hydroxyl, halo, or straight or branched C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, C 1-6 heteroalkyl, C 1-6 aminoalkyl, C 1-6 haloalkyl , C1-6 alkylthio, C1-6 alkoxycarbonyl, -CN, -CF3, -OR3, -COR3, NO2, -NHR3, -NHC (O) R3, -C (O) NR3R4, -NR3R4, -NR3C (O) NR4R5, -OC (O) R3, -C (O) R3R4, -O (CH2) qNR3, -CNR3R4 or - (CH2) qNR3R4; where q is an integer from 1 to 6; n is 0, 1, 2, 3, or 4, the groups R2, when> 1, are the same or different; p is 0 or an integer from 1 to 5; Y is O, S, CHOH, -NHC (O) -, -C (O) NH-, -C (O) -, -OC (O) -, NR7 or -CH = N-, and R7 is H or C1-4 alkyl; absent Z is CR8R9 wherein R8 and R9 are independently selected from H and straight or branched C1-8 alkyl; provided that when - (CH2) p-Y- is- (CH2) 3-C (O) - or - (CH2) 3-S-, and X1 to X5 are C; that -A- (R2) n and R1 are not together: o-methyl-phenyl and n-butyl, respectively; phenyl and n-butyl, respectively;
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/933,177 US20080108618A1 (en) | 1998-03-31 | 2007-10-31 | Compounds with activity on muscarinic receptors |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8013398P | 1998-03-31 | 1998-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR014974A1 true AR014974A1 (en) | 2001-04-11 |
Family
ID=22155464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990101516A AR014974A1 (en) | 1998-03-31 | 1999-04-05 | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINE |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1068185A1 (en) |
JP (1) | JP2002509918A (en) |
KR (2) | KR20060120715A (en) |
CN (1) | CN1303376A (en) |
AR (1) | AR014974A1 (en) |
AU (1) | AU762726B2 (en) |
BR (1) | BR9909277A (en) |
CA (1) | CA2326804C (en) |
MX (1) | MXPA00009569A (en) |
NO (1) | NO319835B1 (en) |
NZ (2) | NZ507204A (en) |
RU (2) | RU2230740C2 (en) |
WO (1) | WO1999050247A1 (en) |
ZA (1) | ZA200005149B (en) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
US6624162B2 (en) | 2001-10-22 | 2003-09-23 | Pfizer Inc. | Imidazopyridine compounds as 5-HT4 receptor modulators |
ES2251624T3 (en) | 2001-12-28 | 2006-05-01 | Acadia Pharmaceuticals Inc. | ANALOGS OF TETRAHYDROQUINOLINE AS MUSCARINIC AGONISTS. |
US7550459B2 (en) | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
MXPA03000145A (en) | 2002-01-07 | 2003-07-15 | Pfizer | Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators. |
GB0211230D0 (en) | 2002-05-16 | 2002-06-26 | Medinnova Sf | Treatment of heart failure |
CA2499494A1 (en) | 2002-09-20 | 2004-04-01 | Pfizer Inc. | N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators |
DOP2003000703A (en) | 2002-09-20 | 2004-03-31 | Pfizer | IMIDAZOPIRADINE COMPOUNDS AS 5-HT4 RECEIVER AGONISTS |
HU227534B1 (en) | 2003-08-04 | 2011-08-29 | Richter Gedeon Nyrt | (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them |
WO2005016276A2 (en) * | 2003-08-05 | 2005-02-24 | Samaritan Pharmaceuticals Inc. | Sigma-1 receptor ligand with acetylcholinesterase inhibition properties |
US7932272B2 (en) | 2003-09-30 | 2011-04-26 | Eisai R&D Management Co., Ltd. | Antifungal agent containing heterocyclic compound |
GEP20084550B (en) | 2004-04-30 | 2008-11-25 | Warner Lambert Co | Substituted morpholine compounds for the treatment of central nervous system disorders |
US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
MXPA06014486A (en) | 2004-06-15 | 2007-03-01 | Pfizer | Benzimidazolone carboxylic acid derivatives. |
ME02222B (en) | 2004-12-30 | 2016-02-20 | Janssen Pharmaceutica Nv | Piperidine- and piperazine-1-carboxylic acid amide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions |
US8110573B2 (en) | 2004-12-30 | 2012-02-07 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases |
US7829585B2 (en) | 2005-03-30 | 2010-11-09 | Eisai R&D Management Co., Ltd. | Antifungal agent containing pyridine derivative |
JP2009506069A (en) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | Neurogenesis through modulation of muscarinic receptors |
EP1939189A4 (en) | 2005-08-26 | 2013-03-13 | Shionogi & Co | Derivative having ppar agonistic activity |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
TWI385169B (en) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | Heterocyclic substituted pyridine derivatives and antifungal agent containing same |
EP1968579A1 (en) | 2005-12-30 | 2008-09-17 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2008001115A2 (en) | 2006-06-29 | 2008-01-03 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea |
CL2008000119A1 (en) | 2007-01-16 | 2008-05-16 | Wyeth Corp | COMPOUNDS DERIVED FROM PIRAZOL, ANTAGONISTS OF THE NICOTINIC ACETILCOLINE RECEIVER; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS SENILE DEMENTIA, ALZHEIMER AND SCHIZOPHRENIA. |
HUP0700353A2 (en) | 2007-05-18 | 2008-12-29 | Richter Gedeon Nyrt | Metabolites of (thio)carbamoyl-cyclohexane derivatives |
US7875610B2 (en) | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
US8513287B2 (en) | 2007-12-27 | 2013-08-20 | Eisai R&D Management Co., Ltd. | Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same |
AP2975A (en) | 2008-07-16 | 2014-09-30 | Richter Gedeon Nyrt | Pharmaceutical formulations containing dopamine receptor ligands |
HU230067B1 (en) | 2008-12-17 | 2015-06-29 | Richter Gedeon Nyrt | Novel piperazine salt and preparation method thereof |
HUP0800765A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Nyrt | A new process for the preparation of piperazine derivatives and their hydrochloric salts |
HUP0800766A2 (en) | 2008-12-18 | 2010-11-29 | Richter Gedeon Vegyeszet | Process for the preparation of piperazine derivatives |
UA108233C2 (en) | 2010-05-03 | 2015-04-10 | Fatty acid amide hydrolysis activity modulators | |
GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
CN102558026A (en) * | 2011-12-27 | 2012-07-11 | 盛世泰科生物医药技术(苏州)有限公司 | Synthesis and optimized process of 4-N-butyl-1-[4-(2-methylphenyl)-4-one-1-butyl]piperidine. N-benzyl-4-piperidone (1) |
US8912197B2 (en) | 2012-08-20 | 2014-12-16 | Forest Laboratories Holdings Ltd. | Crystalline form of carbamoyl-cyclohexane derivatives |
CN102997438A (en) * | 2012-10-16 | 2013-03-27 | 李誊 | Control method of electric water heater for improving heat utilization ratio |
GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
CN105073728A (en) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | Compounds and uses thereof for the modulation of hemoglobin |
EA201992707A1 (en) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION |
CN105829310B (en) | 2013-12-20 | 2019-04-12 | 阿斯特克斯治疗有限公司 | Bicyclic heterocycles and its therapeutical uses |
US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
CN111093662B (en) | 2017-06-20 | 2023-10-03 | 安布里亚制药公司 | Compositions and methods for improving cardiac metabolic efficiency |
US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2695295A (en) * | 1952-12-19 | 1954-11-23 | Mcneilab Inc | Unsymmetrical n, n'-substituted ethylenediamine and piperazine compounds |
GB874206A (en) * | 1956-09-05 | 1961-08-02 | Knoll Ag | Basic derivatives of salicylamide |
NL271658A (en) * | 1960-12-01 | |||
FR1382425A (en) * | 1963-01-14 | 1964-12-18 | Ciba Geigy | Process for preparing diaza-cyclo-alkanes, inter alia 3-methyl-4-phenyl-1- (2-phenylmercapto-ethyl) -piperazine |
GB1053301A (en) * | 1963-01-14 | |||
US3488352A (en) * | 1966-10-11 | 1970-01-06 | Shulton Inc | Basically substituted alkoxy anthranilamides,their corresponding 2-nitro compounds and derivatives thereof |
FR1543944A (en) * | 1967-03-10 | 1968-10-31 | Bruneau & Cie Lab | Salicylic acid amide derivatives and their preparation |
BE792187A (en) * | 1971-12-03 | 1973-03-30 | Sumitomo Chemical Co | NEW ALKYLAMINE DERIVATIVES |
DE2335432A1 (en) * | 1973-07-12 | 1975-01-30 | Boehringer Mannheim Gmbh | 3,4-DIHYDRO-2H-NAPHTHALINONE- (1) 5-OXY-PROPYL-PIPERAZINE DERIVATIVES AND THE METHOD FOR THEIR PRODUCTION |
GB1459506A (en) * | 1974-02-18 | 1976-12-22 | Wyeth John & Brother Ltd | Piperidine derivatives |
GB1498884A (en) * | 1975-04-15 | 1978-01-25 | Wyeth John & Brother Ltd | Aminoacetamide-pyridyl-tetrahydropyridyl and-piperidyl derivatives |
IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
JP3390179B2 (en) * | 1996-08-15 | 2003-03-24 | シェーリング コーポレイション | Ether muscarinic antagonist |
-
1999
- 1999-03-31 RU RU2000127105/04A patent/RU2230740C2/en active
- 1999-03-31 BR BR9909277-8A patent/BR9909277A/en not_active Application Discontinuation
- 1999-03-31 KR KR1020067023572A patent/KR20060120715A/en not_active Application Discontinuation
- 1999-03-31 CN CN99806618A patent/CN1303376A/en active Pending
- 1999-03-31 NZ NZ507204A patent/NZ507204A/en unknown
- 1999-03-31 AU AU32187/99A patent/AU762726B2/en not_active Ceased
- 1999-03-31 MX MXPA00009569A patent/MXPA00009569A/en active IP Right Grant
- 1999-03-31 WO PCT/US1999/007057 patent/WO1999050247A1/en active IP Right Grant
- 1999-03-31 KR KR1020007010780A patent/KR100672186B1/en not_active IP Right Cessation
- 1999-03-31 JP JP2000541152A patent/JP2002509918A/en not_active Withdrawn
- 1999-03-31 NZ NZ525108A patent/NZ525108A/en unknown
- 1999-03-31 EP EP99914306A patent/EP1068185A1/en not_active Withdrawn
- 1999-03-31 CA CA002326804A patent/CA2326804C/en not_active Expired - Fee Related
- 1999-04-05 AR ARP990101516A patent/AR014974A1/en not_active Application Discontinuation
-
2000
- 2000-09-26 ZA ZA200005149A patent/ZA200005149B/en unknown
- 2000-09-29 NO NO20004912A patent/NO319835B1/en unknown
-
2004
- 2004-03-11 RU RU2004107218/04A patent/RU2278111C2/en active
Also Published As
Publication number | Publication date |
---|---|
WO1999050247A1 (en) | 1999-10-07 |
NZ507204A (en) | 2003-12-19 |
MXPA00009569A (en) | 2002-08-06 |
EP1068185A1 (en) | 2001-01-17 |
RU2004107218A (en) | 2005-08-20 |
NO20004912D0 (en) | 2000-09-29 |
KR100672186B1 (en) | 2007-01-19 |
JP2002509918A (en) | 2002-04-02 |
BR9909277A (en) | 2001-10-16 |
KR20060120715A (en) | 2006-11-27 |
ZA200005149B (en) | 2002-01-08 |
CA2326804C (en) | 2006-05-02 |
NO20004912L (en) | 2000-11-23 |
AU762726B2 (en) | 2003-07-03 |
RU2278111C2 (en) | 2006-06-20 |
KR20010042248A (en) | 2001-05-25 |
NO319835B1 (en) | 2005-09-19 |
NZ525108A (en) | 2005-02-25 |
AU3218799A (en) | 1999-10-18 |
CN1303376A (en) | 2001-07-11 |
CA2326804A1 (en) | 1999-10-07 |
RU2230740C2 (en) | 2004-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR014974A1 (en) | COMPOUNDS WITH ACTIVITY ON MUSCARINIC RECEPTORS, A PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINE | |
AR035617A1 (en) | COMPOUNDS DERIVED FROM PHENETHANOLAMINE, COMBINATIONS AND PHARMACEUTICAL FORMULATIONS OF THE SAME, PROCESS FOR THEIR PREPARATION, ITS USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OR PROPHYLAXIS OF A CLINICAL CONDITION FOR WHICH A BETAIEPAR BARDIAR AGENT IS ADDED | |
ES2604947T3 (en) | Compounds of pyrazin-2-yl-pyridin-2-yl-amine and pyrazin-2-yl-pyrimidin-4-yl-amine and their use | |
CR10145A (en) | USEFUL TROPANAN DERIVATIVES IN THERAPY (DIVISIONAL EXP. 6800) | |
AR011229A1 (en) | ADENOSINE-DERIVED COMPOUNDS ANTAGONISTS IN THE AI ADENOSINE RECEPTOR, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN MEDICINE. | |
AR017457A1 (en) | COMPOUNDS DERIVED FROM 2- (PURIN-9-IL) -TETRAHIDROFURAN-3,4-DIOL, PROCESSES FOR THEIR PREPARATION, COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THERAPY FOR THE TREATMENT OF INFLAMMATORY DISEASES. | |
RS51574B (en) | PYRROLO (2,3-d)PYRIMIDINE COMPOUNDS | |
DE69011628T2 (en) | 1,2-Benzisoxazole derivatives, processes for their preparation and pharmaceutical compositions containing them. | |
AR018634A1 (en) | BENZO DERIVATIVES (B) TIEPIN-1,1, -DIOXIDE, PROCEDURE FOR PREPARATION, MEDICATIONS CONTAINING THESE COMPOUNDS, PROCEDURE FOR PREPARATION OF MEDICINES AND THEIR EMPLOYMENT FOR PREPARATION OF MEDICINES. | |
DE69127556D1 (en) | ANTIATHEROSCLEROTIC ARYL COMPOUNDS | |
AR012488A1 (en) | A COMPOUND DERIVED FROM QUINO- AND QUINAZOLINS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR, A PROCEDURE FOR THEIR PREPARATION, A COMPOSITION THAT INCLUDES THEM, A PROCEDURE FOR THE PREPARATION OF SUCH COMPOSITION, INTERMEDIARIES AND THE USE OF SUCH COMPOUNDS. | |
ES2084129T3 (en) | NEW HETERO CYCLIC CALCONS, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
MX9100675A (en) | 2-AMINO-1,2,3,4-TETRAHIDRONAFTALENOS, 3-AMINOCROMANOS AND 3-AMINOTIOCROMANOS SUBSTITUTED IN THE RING, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM | |
PT790248E (en) | 3-AZA-PIPERIDONE- (TETRA-HYDROPYRIMIDIN-2-ONA) AND 3-OXA-PIPERIDONE (1,3-OXAZIN-2-ONA) DERIVATIVES ITS PREPARATION AND USE AS TACHYCININ ANTAGONISTS / NEUROCININ | |
ES543421A0 (en) | A PROCEDURE FOR PREPARING 1,3,4,5-TETRAHYDRO-BENZ (CD) INDOLAMINES OXYGENATED IN POSITION 6 | |
BR0111240A (en) | Stabilizing mixtures | |
ES2119106T3 (en) | NEW BENZO-ESPIRO-ALQUENOS, THEIR PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
ES2063117T3 (en) | DERIVATIVES OF TIENO (2,3-D) ACCEPT, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
AR036351A1 (en) | ISOXAZOLOPIRIDINONAS, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, COMPOSITIONS AND PHARMACEUTICAL COMBINATIONS | |
AR016501A1 (en) | INHIBITING COMPOUNDS OF THE FKBP, PHARMACEUTICAL COMPOSITIONS, USE FOR THE PREPARATION OF MEDICINES AND PROCESSES OF PREPARATION AND INTERMEDIARIES. | |
AR037976A1 (en) | SULFONAMIDS CONTAINING REPLACED PHENYLL WITH HETEROCICLICAL GROUPS, A PHARMACEUTICAL COMPOSITION, A PRODUCT COMBINED WITH AN ANTIRRETROVIRAL AGENT AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. | |
ES2058275T3 (en) | BICYCLE DERIVATIVES OF SULFONAMIDE AND ITS PREPARATION, USE AND FORMULATIONS CONTAINING THEM. | |
SE8604349D0 (en) | DIKLORANILINDERIVAT | |
PT1095940E (en) | CONTAINS DERIVATIVES OF 9- (3,5-DIMETOXYPHENYL) -5,8,8A, 9-TETRAHYDROFUR [3 ', 4': 6,7] NAFTO [2,3- D] [1,3] DIOXOL- 6 (5AH) -one, a process for their preparation and the pharmaceutical compositions which the | |
MX9405111A (en) | NEW DERIVATIVES OF (1-PHENYL-1-HETEROCICLIL) METHANOL AND (1-PHENYL-1-HETEROCICLIL-METHYLAMINE). |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |